DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

Information source: University Hospital, Caen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

Intervention: [18F] - Fludarabine PET/CT (Other)

Phase: Phase 1

Status: Recruiting

Sponsored by: University Hospital, Caen

Official(s) and/or principal investigator(s):
Sylvain P CHANTEPIE, MD, Principal Investigator, Affiliation: University Hospital, Caen


The application of positron emission tomography with lymphoproliferative diseases today provides diagnostic and therapeutic information of major importance , especially in terms of speed and quality of response to treatment. The radiopharmaceutical used in clinical practice for this exam is fluorodeoxyglucose 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose ([18F]-FDG) . However , the uptake of this tracer is not elective in lymphoid tissues , with a lack of specificity. In addition , the avidity of this tracer is unequal according to the histological subtype (lack of sensitivity). To try to improve the results of this clinical exploration of lymphoid malignancies, the

investigators developed a new radiopharmaceutical ( [18F] - fludarabine ). The idea of

transforming the fludarabine radiopharmaceutical is based on the existence of a fluorine atom in the molecule and the pharmacokinetic characteristics of this drug. The [18F]-Fludarabine is a new radiopharmaceutical reproducing the same dosage formulation of fludarabine , a drug used for the treatment of certain types of lymphoproliferative diseases, especially those where the tumor cells have a low proliferation kinetics . This drug is used in therapy in particular pharmacokinetic effect for a high affinity for the

lymphoid tissue . Preclinical results on normal and lymphoma xenograft - bearing mice showed

a specificity restricted to lymphoid tissue fixation with [18F]-Fludarabine compared with [18F]-FDG . Based on these encouraging results , the investigators propose in this work to explore the

Dosimetry and Biodistribution of [18F] - Fludarabine in human lymphoproliferative diseases :

1)A first group of patients with non-Hodgkin's large cell lymphomas in which it already has a wealth of experience in exploration [18F]-FDG, and 2) a second group of patients with chronic lymphocytic leukemia, where the results of the exploration [18F]-FDG are considered disappointing and did not, for this reason, experienced clinical development.

Clinical Details

Official title: Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

Study design: Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Standardized measure of [18F]-Fludarabine uptake in tumor tissue.

Secondary outcome: Calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Adult over 18

- Signed written informed consent

- Untreated stage B or C chronic lymphocytic leukemia

- Untreated diffuse large B-cell lymphoma

- Eligible for PET-CT

- The subject must be covered by a social security system

Exclusion Criteria:

- Age under 18

- Patients concurrently included in an investigational trial

- Weight over 120 kg

- pregnant women

- active infectious disease

- immune hemolytic anemia

- patients with creatinine clearance < 30 ml/mn

- corticosteroid therapy

Locations and Contacts

University Hospital, Caen 14000, France; Recruiting
Sylvain P Chantepie, MD, Phone: +33231272073, Email: chantepie-s@chu-caen.fr
Sylvain P Chantepie, MD, Principal Investigator
Additional Information

Starting date: April 2014
Last updated: February 4, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017